echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Aiming at pharmaceutical opportunities in 2020 Starting with optimizing the market access architecture?

    Aiming at pharmaceutical opportunities in 2020 Starting with optimizing the market access architecture?

    • Last Update: 2020-08-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the background of thin profits in medicine, the epidemic caused the pharmaceutical industry to worse, "survival of the fittest" will be fully presented.
    in order to survive, enterprises are forced to optimize the access structure, promote enterprises to quickly adapt to the changing environment, to find vitality.
    operations, market access is the key link, to undertake research and development and marketing, market access success or not related to product life cycle management.
    , market access changes and unchanged drug companies have set up market access departments, different definitions, different functions.
    1. The market access department of general domestic pharmaceutical companies presents central government affairs, regional government affairs, responsible for bidding, pricing, central government affairs, regional government affairs, a director with several managers, directors out of 60-800,000 / year, managers general salary of 20-300,000 / year.
    2. In the process of change, enterprise market access is more important and more segmented, and needs to be continuously optimized in order to adapt to the environment: (1) the central government affairs team, connected to the health insurance, health, development and reform commission, industry and information technology departments, is generally responsible for drug collection, medical insurance catalogue, medical and health business, the circulation of base drugs and national policy analysis and forecasting.
    , the National Policy and Analysis Team is the most important, providing access environmental analysis, developing access strategies, action plans, policy trend forecasts, and communicating China policy changes to global headquarters.
    (2) access business team, docking marketing system, responsible for each marketing system of product access strategy, with the business department head and marketing department to communicate the feasibility of the business unit access strategy.
    (3) local access strategy team, but also to the provincial health, health care related departments.
    responsible for the landing of a central access strategy and the development of regional market access strategies.
    (4) MarketingAccess Operations, an access strategy operations team responsible for access strategy innovation, access project design, new product pricing, and drug economics, is the most focused team.
    the high degree of specialization, product pricing and drug economics are higher than the general access function.
    2. Possible market access opportunities 1. Job opportunities for the central government affairs team: (1) Health insurance team: "Interim Measures for the Administration of Basic Medical Insurance Drugs" will be released soon, there may be the following changes: the medical insurance directory is adjusted to once a year, while accepting corporate declarations, bidding access is also a bright spot, a few words, worthy of the central government affairs team in-depth study, for enterprises to strive for access opportunities.
    , especially the central government's access strategy, needs to be highly consistent with the health care management approach.
    (2) National Collection Team: With the expansion of the scope of national harvesting, the increase in price reduction, the impact on enterprises more significant.
    April 23, 2020 CDE announced the 28th batch of generic drug consistency evaluation catalog, generic drugs into the collection without luck, is inevitable.
    how to delay access to the collection catalog or actively enter the collection catalog, and how to deal with the introduction of collection rules will also be an important topic for the national collection team research.
    (3) Health team: "National Basic Medicines Catalog" or adjustment, basic drugs all included in the medical insurance directory to make the value-added of basic drugs a lot, in the Health and Health Commission has issued a document, emphasizing the 1 x drug use program, highlighting the status of basic drug use, the development of grade hospital basic drug use ratio, while including in the hospital assessment and management.
    in addition to the need to consider the "Focus Monitoring Drug Catalog" update or the second batch of publication.
    (4) Other: Opportunities for special drug policies such as rare diseases, shortages, and other sector-related policies will find access.
    2. Access to business team job opportunities: This part of the work is the most grounded, the impact on the business is greater.
    Evaluating competitors' possible responses, based on different policies and combining the strengths and weaknesses of an enterprise's products, is not only an internal team analysis and idea, but also a need to coordinate with the relevant business unit leader or marketing department to best test horizontal communication and collaboration capabilities."
    e.g. "Deepening the reform of the medical security system" pointed out that the exploration of rare disease drug protection mechanism, and for haemophilia patients, we know that a head drug company products have not yet entered the national health insurance catalog, and competitive products have been accessed, I believe that this part of the work should not be completed independently, there is collective wisdom, this work is worth further discussion.
    3. Job opportunities for local access strategy teams: "Pharmaceutical policies tend to be unified, with regionalization and regional pilots."
    health insurance catalogue will tend to be unified in the future, and collection and other policies have a regional trend.
    such as Hainan Province Medical Security Bureau and other four ministries announced the second batch of collection and procurement program pointed out that, "in the procurement cycle has completed the completion of the amount of the remaining amount of the amount of the province's drug centralized procurement management, the appropriate amount of procurement of the same varieties of appropriate prices of other varieties, but in principle the use of selected drugs is not lower than the purchase of non-successful drugs."
    " this part leaves some opportunities for local access teams.
    These, location determines market access pre-management pharmaceutical industry competition forward, the more in the front end, the more in the forward, high importance, strong destructive power;
    research and development pipeline in the clinical research layout, affecting the development of enterprises for five to ten years or more, once the pipeline layout lost, the loss is billions or even billions.
    , Hengrui, sunny outbursts are not a day's work.
    the end of the sales, on the quarter, this year's earnings have an impact, do not do well may be local or a pipeline, but not to the pharmaceutical companies hurt bones.
    market access and research and development are similar, front-end access layout affects the product launch process.
    market access will drive product launch success, especially if the architecture is optimized.
    enterprises in the market trend after a full understanding, in the new product market process should do: trend and change in the win.
    China's pharmaceutical market is a continuous trend of change, and unstoppable, enterprises should adapt to the situation, for new products to market to carry out customized special work, including short-term screening of treatment areas and varieties, redefining market access and optimize market access structure.
    today's Chinese pharmaceutical market, "the fittest survival, changer wins!" "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.